With the passage of the Pharmacare Act, Innovative Medicines Canada remains concerned that the pharmacare program as outlined in the bill will not achieve its intended outcomes, and has potential to negatively impact Canadians’ access to new, innovative treatments.
Many Canadians have coverage through both public and private health plans. Several employer plans cover a broad range of medications, providing a safety net for millions. However, if pharmacare adopts a one-size-fits-all solution, there is a risk that Canadians could lose access to more comprehensive options. A public formulary may limit the number of available drugs, particularly affecting those who rely on cutting-edge therapies.
For pharmacare to succeed, we encourage provincial governments to actively engage in bilateral negotiations with the federal government, ensuring that solutions reflect the specific health needs of their populations. A tailored approach will allow provinces to focus on closing coverage gaps, without dismantling systems that are already working well for many Canadians. This type of strategic, gap-filling approach ensures that pharmacare funds are used to address real, unmet needs, rather than duplicating existing services or altering service coverage.
As the Government of Canada continues to work with provinces and territories to implement the newly passed pharmacare legislation, the focus must remain on the patients who need timely access to innovative life-changing medications. Their needs should guide the creation of a robust, inclusive pharmacare system that ensures no Canadian is left waiting for the cutting-edge treatments they need. IMC will continue to work with government and interested parties to improve access to lifesaving treatments and medicines for all Canadians.
About Innovative Medicines Canada
Innovative Medicines Canada (IMC) is the national association representing Canada’s innovative pharmaceutical industry. The industry proudly supports over 100,000 high-value jobs, contributes a total of $16 billion to the economy, sponsors the majority of clinical trials in Canada, and invests close to $3 billion in research and development each year. IMC advocates for policies that enable the discovery, development, and delivery of innovative medicines and vaccines to improve the lives of all Canadians. The association and its members are committed to being solutions-oriented partners in Canada’s healthcare system and have contributed over $30 million towards applied health systems research through the Health Research Foundation (HRF). Guided by the Code of Ethical Practices, all members work with governments, private payers, healthcare professionals, and stakeholders in a highly ethical manner.
For further information: media@imc-mnc.ca
